Loading...
TerrAscend Corp.
TER.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$2.38
CA$-0.01(-0.42%)

Over the last four quarters, TerrAscend Corp. achieved steady financial progress, growing revenue from $117.90M in Q4 2023 to $74.17M in Q3 2024. Gross profit stayed firm with margins at 49% in Q3 2024 versus 45% in Q4 2023. Operating income totaled $2.45M in Q3 2024, maintaining a 3% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $7.30M. Net income dropped to -$23.15M, with EPS at -$0.08. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan